INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
Portfolio Pulse from
Pomerantz LLP has filed a class action lawsuit against Intellia Therapeutics (NTLA) alleging potential securities fraud. The lawsuit stems from the company's January 9, 2025 announcement of strategic changes, including discontinuing NTLA-3001 drug development, cutting 27% of workforce, and the retirement of its Chief Scientific Officer. The stock price dropped 15.14% following this news.
April 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Class action lawsuit filed alleging potential securities fraud related to strategic changes and workforce reduction
The class action lawsuit, combined with significant corporate restructuring and stock price drop, suggests potential negative short-term market sentiment for Intellia Therapeutics
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100